William Chase
Intellia TherapeuticsAbout William Chase
Independent director at Intellia Therapeutics since April 2023; age 57. Former EVP, Finance & Administration (2018–2019) and CFO (2012–2018) of AbbVie, with prior senior finance, treasury, and licensing roles at Abbott. Holds a B.S. in Finance (University of Illinois) and MBA (University of Chicago). Board tenure ~2 years at Intellia; designated Audit Committee financial expert and brings deep pharmaceutical finance and M&A expertise .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| AbbVie Inc. | EVP, Finance & Administration | Oct 2018–Jul 2019 | Oversaw finance, IR, IT; strategic role in licensing/M&A |
| AbbVie Inc. | EVP & CFO | 2012–2018 | Led key financial functions; strategic deal-making |
| Abbott Laboratories | Corporate VP, Licensing & Acquisitions; Corporate VP, Treasurer; Divisional VP & Controller, Abbott International | Prior to 2012 | Led L&A, treasury; international finance leadership |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Parexel International Corporation | Director | Current | CRO sector; private company |
| GRAIL, Inc. | Director | Current | Oncology diagnostics; private company |
Board Governance
- Committee assignments: Audit Committee member and Chair; Compensation & Talent Development Committee member (served as interim chair in 2024) .
- Independence: Board determined Chase is independent under Nasdaq and SEC rules .
- Attendance: Board met 5 times in 2024; all directors attended ≥75% of board and committee meetings; all directors attended the 2024 annual meeting .
- Board leadership: Separate Chair (Frank Verwiel) and CEO structure; risk oversight via committees; Chase signs the Audit Committee Report as Chair .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| 2024 Cash Fees (William Chase) | $80,000 | Comprised of board retainer and committee member/chair fees per policy |
| Board Retainer (member) | $45,000 | Annual cash |
| Board Chair additional | $35,000 | Not applicable to Chase |
| Audit Committee: member / chair | $10,000 / $10,000 | Chase served as chair in 2024 |
| Compensation Committee: member / chair | $7,500 / $7,500 | Chase interim chair in 2024; member thereafter |
| Nominating Committee: member / chair | $5,000 / $5,000 | Not applicable to Chase |
| Science & Technology Committee: member / chair | $7,500 / $7,500 | Not applicable to Chase |
Performance Compensation
| Equity Award (2024) | Quantity | Grant Date Fair Value | Vesting | Notes |
|---|---|---|---|---|
| Stock Options | 11,515 shares | $199,926 | Annual director grants vest by next annual meeting (~1 year) | Options priced at fair market value on grant |
| RSUs | 7,737 units | $200,001 | Annual director grants vest by next annual meeting (~1 year) | No dividends on unvested awards |
| Director compensation cap | $1,000,000 per year | — | — | Applies to cash + equity under 2025 Plan |
| CIC treatment (directors) | Full vesting upon change in control | — | Single-trigger | Distinct from employee “double trigger” in 2025 Plan |
Other Directorships & Interlocks
| Company | Sector Relationship to NTLA | Potential Interlock/Conflict |
|---|---|---|
| Parexel International Corporation | CRO/services | No related-party transactions disclosed; audit committee reviews any related transactions |
| GRAIL, Inc. | Diagnostics | No related-party transactions disclosed |
Expertise & Qualifications
- Financial expert (SEC definition) designated by the board; chairs Audit Committee .
- Extensive pharma industry finance and corporate development background; led major licensing and acquisitions at AbbVie/Abbott .
- Public company governance experience; contributes to strategy, oversight of financial reporting, risk management .
Equity Ownership
| Component | Shares | % Outstanding | Details |
|---|---|---|---|
| Common stock (direct) | 11,093 | <1% | As of March 31, 2025 |
| RSUs vesting within 60 days | 874 | <1% | Included in beneficial ownership |
| Options exercisable within 60 days | 12,401 | <1% | Included in beneficial ownership |
| Total beneficial ownership | 24,368 | <1% | SEC beneficial ownership table |
| Hedging/pledging policy | Prohibits short sales, derivatives, and pledging without Audit Committee approval | — | Ownership guidelines: 3x annual retainer; phase-in to 2027/5-year mark |
Governance Assessment
- Strengths: Independent director; Audit Committee financial expert; chairs Audit Committee; clean related-party profile; strong attendance; robust insider trading/hedging controls; director equity capped at $1M; clawback policy applies to awards under 2025 plan; strong say-on-pay support (97.9% in 2024) indicating overall governance alignment .
- Considerations: Single-trigger full vesting of director equity upon change in control (less investor-friendly than double-trigger); multiple external board commitments require continued monitoring by Nominating & Corporate Governance Committee (which oversees external commitments) to ensure sustained engagement .
RED FLAGS: None disclosed regarding related-party transactions, hedging/pledging, or attendance; single-trigger CIC vesting for directors noted as a governance consideration .